- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Journal: Focal and diffuse myocardial fibrosis both contribute to regional hypoperfusion assessed by post-processing quantitative-perfusion MRI techniques. (Pubmed Central) - Oct 5, 2023
In addition to the clinical report, MBF during regadenoson-stress was quantified using a post-processing QP method and T1 maps were used to calculate ECV...Quantitative analysis of MBF and diffuse fibrosis detected regional tissue abnormalities not identified by traditional visual assessment. Multi-parametric quantitative analysis may refine the work-up of the etiology of myocardial ischemia in patients referred for clinical CMR stress testing in the future and provide a deeper insight into ischemic heart disease.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Phase classification: Regadenoson Real Time Perfusion Imaging Trial-Optison (clinicaltrials.gov) - Oct 3, 2023
P3, N=50, Completed,
Multi-parametric quantitative analysis may refine the work-up of the etiology of myocardial ischemia in patients referred for clinical CMR stress testing in the future and provide a deeper insight into ischemic heart disease. Phase classification: P=N/A --> P3
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Preclinical, Journal: Regadenoson for the treatment of COVID-19: A five case clinical series and mouse studies. (Pubmed Central) - Aug 15, 2023
We speculate that iNKT cells are activated by release of injury-induced glycolipid antigens and/or alarmins such as IL-33 derived from virally infected type II epithelial cells which in turn activate iNKT cells and secondarily other immune cells. Adenosine released from hypoxic tissues, or RA infused as an anti-inflammatory agent decrease proinflammatory cytokines and may be useful for treating cytokine storm in patients with Covid-19 or other inflammatory lung diseases or trauma.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion date, Trial primary completion date: Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System (clinicaltrials.gov) - Aug 15, 2023
P1, N=46, Recruiting,
Adenosine released from hypoxic tissues, or RA infused as an anti-inflammatory agent decrease proinflammatory cytokines and may be useful for treating cytokine storm in patients with Covid-19 or other inflammatory lung diseases or trauma. Trial completion date: Aug 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jun 2024
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Treat COVID-19 Patients With Regadenoson (clinicaltrials.gov) - Aug 15, 2023
P1/2, N=5, Completed,
Trial completion date: Aug 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jun 2024 Recruiting --> Completed | N=40 --> 5 | Trial completion date: Dec 2023 --> Apr 2023 | Trial primary completion date: Jul 2023 --> Apr 2023
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Stressed Into a STEMI (Zone 4, Science and Technology Hall, Level 2) - Aug 12, 2023 - Abstract #AHA2023AHA_3811;
However, resting blood flows are slightly higher when regadenoson is used which may impact quantification of MPR. A regadenson stress test can trigger STEMI in patients with unstable angina however the mechanism is unclear
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion date, Trial primary completion date: Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking (clinicaltrials.gov) - Aug 1, 2023
P4, N=300, Active, not recruiting,
A regadenson stress test can trigger STEMI in patients with unstable angina however the mechanism is unclear Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Journal: The identification of synthetic cannabinoids in English prisons. (Pubmed Central) - Jun 16, 2023
This research directly benefitted both the West Midlands Prison Group and Rapiscan Systems Ltd. and it is anticipated that the continuation of this research could be expanded to a national scale.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion date, Trial primary completion date: The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI (clinicaltrials.gov) - Apr 3, 2023
P=N/A, N=30, Recruiting,
A fixed-dose bolus administration may not be adequate to induce maximum hyperaemia in patients with increased weight, therefore weight-adjusted stressor like adenosine should be considered instead whenever possible. Trial completion date: Dec 2022 --> Sep 2023 | Trial primary completion date: Dec 2022 --> Sep 2023
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: Treat COVID-19 Patients With Regadenoson (clinicaltrials.gov) - Mar 10, 2023
P1/2, N=40, Recruiting,
Enrolled subjects did not complete study. Trial primary completion date: Jan 2023 --> Jul 2023
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Retrospective data, Journal: Indicators of abnormal PET coronary flow capacity in detecting cardiac ischemia. (Pubmed Central) - Feb 27, 2023
No abstract available Data were examined retrospectively for 231 patients evaluated for known/suspected CAD who underwent rest and regadenoson-stress Rb PET/CT...A Global Index formed from stress ejection fraction, SSS and BW was the most accurate means of identifying patients with global CFC???4 (84?
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking (clinicaltrials.gov) - Feb 27, 2023
P4, N=300, Active, not recruiting,
Data were examined retrospectively for 231 patients evaluated for known/suspected CAD who underwent rest and regadenoson-stress Rb PET/CT...A Global Index formed from stress ejection fraction, SSS and BW was the most accurate means of identifying patients with global CFC???4 (84? Trial primary completion date: Aug 2022 --> Aug 2023
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Journal: Resting coronary flow drives the daily pattern in coronary flow reserve in patients with chest pain without obstructive epicardial stenosis. (Pubmed Central) - Feb 11, 2023
Coronary microvascular function was measured using perfusion contrast imaging at rest and after infusion of intravenous regadenoson...Coronary microvascular flow reserve was ?33% higher in the AM compared to the PM (P = 0.025, BCa 95% CI [0.25, 1.64]; Hedge's g = 0.89, 95% CI [0.11, 1.66]) as a result of significantly lower resting flow (?50%) in the AM compared to the PM (P = 0.03, M = -56.65, BCa 95% CI [-118.59, -2.12]; Hedge's g = -0.86, 95% CI [-1.60, -0.06]). Our observations are of clinical value and can influence diagnosis and treatment in the clinic based on the time of day of measurements.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
CORONARY MICROVASCULAR DYSFUNCTION IN A PATIENT WITH AORTIC STENOSIS DIAGNOSED BY MULTIMODAL IMAGING (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_4875;
Microcirculatory dysfunction in patients with aortic stenosis may explain angina symptoms in absence of obstructive coronary artery stenosis. The use of Cardiac PET imaging is a non-invasive imaging tool that can aid in establishing the diagnosis of coronary microvascular disease.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
UTILIZATION OF PEAK STRESS FEATURE TRACKING CARDIAC MAGNETIC RESONANCE IMAGING IN IDENTIFYING MYOCARDIAL FIBROSIS (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_4780;
Patients who underwent regadenoson stress CMR testing over the course of a year (01/2018-12/2018) were retrospectively identified... Myocardial strain is a well-documented measure of cardiac function and though regional differences exist even in a healthy myocardium, a significant alteration in myocardial deformation is exhibited in segments with fibrosis with the worst function noted where extent of LGE was >75%.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
A CASE OF REGADENOSON INDUCED STEMI (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_3732;
Vasodilator stress test induced coronary steal syndrome with ST segment elevations clinically signifies critical proximal stenosis with collateral flow to viable myocardium, as seen in our patient. These patients should undergo immediate coronary angiography before myocardial injury progresses to complete infarction.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
IS MYOCARDIAL BRIDGING A BENIGN EVENT? (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_3727;
We present two cases of MB where surgical intervention was required. In cases of MB causing intractable symptoms or MI, surgical intervention is a definitive treatment which can offer relief.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
OPTIMIZATION OF STENT SIZE IN A VERY LARGE CORONARY ARTERY: CAROTID BALLOON SAVED THE DAY (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_2492;
In a very large coronary artery, using non-coronary balloons may be a reasonable choice for optimization of stent expansion. Knowing the available equipment in the cardiac catheterization laboratory is essential to properly manage unusual situations.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
SGLT2 INHIBITOR USE IN HFPEF ASSOCIATED WITH SEVERE SEPSIS AND SEPTIC SHOCK AND A NEW ONSET CARDIOMYOPATHY (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_1881;
Patients should be screened carefully before prescribing these medications. Although life threatening genital infections has been associated with their usage and reported in literature, their association with severe sepsis and septic shock is less well established.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
COMPLETE HEART BLOCK FOLLOWING REGADENOSON INJECTION: UNCOMMON COMPLICATION (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_762;
She was then received 100 mg of IV Aminophylline with complete resolution of her symptoms as well as new ECG changes. Prior ECG review and raised awareness among health care workers in nuclear labs should minimize rare symptomatic events.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: Regadenoson Real Time Perfusion Imaging Trial-Optison (clinicaltrials.gov) - Dec 30, 2022
P=N/A, N=50, Completed,
Prior ECG review and raised awareness among health care workers in nuclear labs should minimize rare symptomatic events. Unknown status --> Completed
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Journal: Post COVID-19 Syndrome with Impairment of Flow-Mediated Epicardial Vasodilation and Flow Reserve. (Pubmed Central) - Nov 19, 2022
The use of regional MFR instead of global MFR is recommended as it improves the diagnostic value of Rb-82 PET in the detection of oCAD. Post-acute sequelae of COVID-19 cardiovascular syndrome may be associated with an impairment of flow-mediated epicardial vasodilation, while reductions in coronary vasodilator capacity appear predominantly related to increases in resting flow in women deserving further investigations.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Review, Journal: Ischemic heart disease : More than just chronic CAD (Pubmed Central) - Nov 3, 2022
AR-stress MRI is used to diagnose myocardial ischemia in combination with viability imaging (LGE). Dobutamine-atropine (DoA) stress MRI is an alternative in the setting of contraindications for AR or specific clinical questions.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: Heart Rate Response to Regadenoson and Sudden Cardiac Death (clinicaltrials.gov) - Oct 18, 2022
P=N/A, N=90, Completed,
Software packages can provide automated measurements of several parameters, particularly contributing to the investigation of cases with ambiguous scintigraphic findings. Active, not recruiting --> Completed
|
